Prominent Gastroparesis Drugs Market Trend for 2025: Development Of Innovative Gastroparesis Treatment

What Are the Projected Growth and Market Size Trends for the Gastroparesis Drugs Market?
In recent times, the gastroparesis drugs market has experienced substantial growth. The market size is projected to expand from $5.39 billion in 2024 to $5.73 billion in 2025, with a compound annual growth rate (CAGR) of 6.3%. Various factors like the side effects associated with current treatments, research into gastrointestinal motility, clinical requirements, patient advocacy efforts and regulatory backing have contributed to the growth historically.

It is projected that the market size for gastroparesis drugs will significantly expand in the coming years, reaching $7.2 billion in 2029 with a compound annual growth rate (CAGR) of 5.9%. This projected growth during the forecast period is attributable to a rise in diabetes cases, an aging demography, heightened awareness and diagnosis rates, elevated healthcare spending, and funding from both government and private sectors. Leading trends for this forecast period consist of progress in gastroenterology, enhanced diagnostic methods, technological innovations, research funding, and collaboration in research endeavors.

What Key Elements Are Boosting Growth in the Gastroparesis Drugs Market?
The gastroparesis drug market is anticipated to see a surge as the incidence of diabetes continues to rise. Diabetes, a chronic health condition characterized by excessive blood sugar levels as a result of insufficient insulin production or ineffective insulin use, is gaining prevalence due to factors like inactive lifestyles, unhealthy food choices, genetics, urbanization, and an aging population. Furthermore, restricted access to healthcare and increasing obesity rates globally are also contributing to this rise in diabetes. Doctors often prescribe gastroparesis drugs for diabetic patients to help manage typical diabetic complications such as feeling sick, throwing up, and slower gastric emptying, all negatively impacting the gastrointestinal motility. These drugs help ameliorate gastric function and boost the quality of life of patients facing gastroparesis due to diabetes. For instance, the UK-based government agency, the Office for Health Improvement & Disparities, revealed that in March 2024, there was a 22% increase in individuals with type 1 diabetes receiving all eight suggested care processes from March 2022 to March 2023. Similarly, in type 2 diabetes patients, it rose by 21%. Meanwhile, the percentage of patients hitting their target HbA1c levels surged to 37.9%, the highest score ever documented by the National Diabetes Audit (NDA). Consequently, the upward trend of diabetes prevalence is triggering the expansion of the gastroparesis drugs market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15812&type=smp

Which Leading Companies Are Shaping the Growth of the Gastroparesis Drugs Market?
Major companies operating in the gastroparesis drugs market are Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA., AstraZeneca plc, Abbott Laboratories, GSK plc, Takeda Pharmaceutical Inc., Teva Pharmaceutical Inc., Otsuka Pharmaceutical Co. Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Evoke Pharma Inc., Cadila Pharmaceuticals, Cipla Ltd., Neurogastrx Inc., Ipca Laboratories Ltd., ANI Pharmaceuticals Inc., Salix Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., Theravance Biopharma Inc., Rhythm Pharmaceuticals Inc., Processa Pharmaceuticals Inc., Aclipse Therapeutics LLC, ETX Pharma Inc.

What Are the Major Trends Shaping the Gastroparesis Drugs Market?
Leading firms in the gastroparesis drugs market are concentrating their efforts on the creation of advanced drugs like Gimoti (metoclopramide) nasal spray, to establish a competitive advantage within the industry. The Gimoti (metoclopramide) nasal spray is a treatment designed to alleviate gastroparesis symptoms in adults by boosting gastrointestinal mobility and thus increasing stomach emptying. Rather than passing through the gastrointestinal tract, the drug is directly absorbed into the bloodstream via the nasal mucosa. For example, in April 2022, Evoke Pharma Inc, an American pharmaceutical corporation, announced that they received approval from the U.S. Food and Drug Administration (FDA) for exclusive marketing of the drug GIMOTI (metoclopramide) nasal spray for three years from the initial endorsement date according to the Hatch-Waxman Act. This exclusivity shields the product from competition with generic versions.

What Are the Key Segments of the Gastroparesis Drugs Market?
The gastroparesis drugs market covered in this report is segmented -

1) By Drug Type: Over-the-counter (OTC) Drugs, Prescription Drugs
2) By Drug Class: Prokinetic Agents, Antiemetic Drugs, Proton Pump Inhibitors, Other Drug Classes
3) By Disease Type: Diabetic Gastroparesis, Post-Surgical Gastroparesis, Idiopathic Gastroparesis, Other Disease Types
4) By Route Of Administration: Oral, Injectables, Other Routes Of Administration
5) By Distribution Channel: Hospitals, Pharmacies, Clinics, E-commerce

Subsegments:
1) Over-the-counter (OTC) Drugs: Antacids, Anti-Nausea Medications, Antiemetics, Digestive Enzyme Supplements
2) Prescription Drugs: Prokinetic Agents, Antiemetic Drugs, Antibiotics, Antidepressants

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

Which Region Dominates the Gastroparesis Drugs Market?
North America was the largest region in the gastroparesis drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroparesis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Is Covered In The Gastroparesis Drugs Global Market Report?

- Market Size Analysis: Analyze the Gastroparesis Drugs Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Gastroparesis Drugs Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Gastroparesis Drugs Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Gastroparesis Drugs Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15812

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.